Improving Outcomes for Patients With Hemophagocytic Lymphohistiocytosis

Affiliations

¹ Anne Burnett Marion School of Medicine at Texas Christian University.
² Department of Pediatric Hematology/Oncology, Cook Children's Medical Center, Fort Worth, Texas. Anish.Ray@CookChildrens.org.

Comment

Meaghan Rousset et al. J Rheumatol. 2023 Jul.

. 2023 Jul;50(7):967.

doi: 10.3899/jrheum.221010. Epub 2022 Nov 15.

¹ Anne Burnett Marion School of Medicine at Texas Christian University.
² Department of Pediatric Hematology/Oncology, Cook Children's Medical Center, Fort Worth, Texas. Anish.Ray@CookChildrens.org.

No abstract available

Comment in

Dr. Degar et al reply.
Degar BA, Halyabar O, Hazen MM, Henderson LA. Degar BA, et al. J Rheumatol. 2023 Jul;50(7):968-969. doi: 10.3899/jrheum.221078. Epub 2022 Nov 15. J Rheumatol. 2023. PMID: 36379573 No abstract available.

An Evidence-Based Guideline Improves Outcomes for Patients With Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome.
Taylor ML, Hoyt KJ, Han J, Benson L, Case S, Chandler MT, Chang MH, Platt C, Cohen EM, Day-Lewis M, Dedeoglu F, Gorman M, Hausmann JS, Janssen E, Lee PY, Lo J, Priebe GP, Lo MS, Meidan E, Nigrovic PA, Roberts JE, Son MBF, Sundel RP, Alfieri M, Yeun JC, Shobiye DM, Degar B, Chang JC, Halyabar O, Hazen MM, Henderson LA. Taylor ML, et al. J Rheumatol. 2022 Sep;49(9):1042-1051. doi: 10.3899/jrheum.211219. Epub 2022 Jul 15. J Rheumatol. 2022. PMID: 35840156 Free PMC article.